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A systematic review of discrete choice experiments and 
conjoint analysis studies in people with Multiple 
Sclerosis 
 
Edward J.D. Webb1,2 David Meads2 Ieva Eskyte3 Natalie King2
 Naila Dracup2 Jeremy Chataway4 Helen Ford5 Joachim 
Marti6 Sue H. Pavitt7 Klaus Schmierer8,9 Ana Manzano10 
 
Abstract 
 
Background: Multiple sclerosis (MS) is a chronic disabling, inflammatory and degenerative 
disease of the central nervous system which, in most cases, requires long term disease 
modifying treatment (DMT). The drugs used vary in efficacy and adverse effect profile. A 
number of studies have used attribute-based stated preference methods, primarily to investigate 
patient preferences for initiating or escalating DMT. 
 
Aims: To conduct a systematic review of attribute-based stated preference studies in people 
with MS to identify common methods employed, and to assess study quality with reference to 
the specific challenges of this disease area. 
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Methods: We conducted a systematic search for studies related to attribute-based stated 
preference and MS in multiple databases including Cochrane and MEDLINE. Studies were 
included if they were published in a peer-reviewed journal, were on the topic of MS and used 
a survey methodology that measured stated preferences for attributes of a whole. Analysis was 
conducted using narrative synthesis and summary statistics. Study quality was judged against 
the ISPOR conjoint analysis checklist. 
 
Results: We identified 16 relevant articles reporting 17 separate studies, all but one focussing 
on DMTs. The majority of studies were discrete choice experiments. The study quality was 
generally high, but recommendations are made to improve: 1) sample size considerations, 2) 
documentation of justification of survey design choices, 3) incorporation of qualitative 
approaches for attribute and level selection to better involve patients, and 4) better reporting of 
experimental practice. The effects of DMTs on reproduction and the impact of presenting risk 
and uncertainty were identified as neglected research topics. The ISPOR conjoint analysis 
checklist was not found to be suitable to assess study quality. 
 
Conclusion: Attribute-based stated preference is a useful method to examine preferences of 
people with MS in their choice of DMT. However, there is a need for further research 
embracing the methodological recommendations identified, particularly greater use of 
qualitative methods in attribute development. 
 
Key points:  
x We conducted a systematic review of discrete choice experiments, conjoint analysis 
and other attribute-based stated preference studies in Multiple Sclerosis. 
x Areas for improvement in future studies are: sample size considerations, documentation 
of justification for design choices, greater use of qualitative methods for attribute/level 
development and better reporting of experimental procedures. 
x Effect of treatment on reproduction and the influence of risk perception were identified 
as understudied topics. 
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1. Introduction 
 
Multiple sclerosis (MS) is a chronic neurological disease and the commonest non-traumatic 
cause of acquired disability in young adults in the Western World [1]. Mean age of onset is 30 
years with over two thirds of patients being female [2]. The aetiology of the disease is not fully 
understood, but it is known to be an inflammatory demyelinating disorder of the central nervous 
system [3]. Most people with MS (PwMS) experience two clinical phases, initially relapsing-
remitting MS (RRMS) followed by a phase with gradual accumulation of disability ± secondary 
progressive MS (SPMS) [4]. Natural history data suggest the clinical phenotype switch from 
RRMS to SPMS usually occurs about 10-15 years after onset [5, 6]. Whilst the clinical hallmark 
of RRMS are relapses followed by a variable degree of remission, SPMS is characterised by 
disability that may affect numerous functions including gait, balance, vision, cognition, and 
continence [7]. In about 10% of PwMS the disease is progressive from onset ± primary 
progressive MS (PPMS) [8]. 
 
Treatments for PwMS fall broadly into two categories: 1) Symptomatic treatments intended to 
alleviate specific symptoms PwMS experience and 2) Disease modifying treatments (DMTs) 
intended to alter the natural course of MS, i.e. reducing the frequency and severity of relapses, 
and slowing of functional deterioration [9]. For DMTs to be effective, PwMS need to commit 
to long term interventions, in many cases requiring regular administration of tablets, injections 
or infusions. 
 
Currently, 14 DMTs are available for the treatment of people with relapsing-remitting MS 
(PwRMS) whilst only one has been approved for people with progressive MS. The drugs used 
vary in efficacy, adverse event profile, mode of delivery and monitoring burden[10].  
 
The increasing number of DMT options creates uncertainty in treatment selection. There is 
little information about how PwMS choose DMTs once an MS diagnosis has been established. 
Several of the most effective DMTs are associated with an increased risk of adverse effects, 
including life-threatening infections and secondary autoimmunity. Patients have to trade-off 
these potential negative consequences with perceived benefits (reduced relapse rate and 
disability accrual, maintained or improved quality of life). Such decisions can be challenging 
at any time, but may be particularly difficult soon after diagnosis when PwMS are coming to 
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terms with the presence of a chronic condition, have less knowledge about MS, how it will 
progress and impact on their quality of life. 
 
The choice of DMT depends greatly on individual preference, requiring weighing-up and 
trading-off different attributes. For example, a decision has to be made whether a reduction in 
the probability of relapses outweighs the risk of a serious side-effect. Attribute-based stated 
preference (AbSP) techniques, such as discrete choice experiments (DCE), best-worst scaling 
(BWS) and conjoint analysis1, may elicit such trade-offs between the individual attributes 
which make up a choice object, and are hence ideal for investigating the DMT preferences of 
PwMS [11]. Given the number of DMTs is still expanding, another advantage of using AbSP 
is that it gives an insight into patient attitudes towards potential treatments that are not yet 
available, and give an indication to those developing and trialling new drugs on what 
combination of attributes would be acceptable to PwMS. 
 
The above describes why MS is a fertile grounds for AbSP research. However, it is also 
uniquely challenging. MS is categorized into distinct clinical phenotypes and is a progressive 
disease with a wide range of symptoms, resulting in a highly individual experience for PwMS. 
The benefits of treatment are probabilistic: no drug is effective in every case, so every decision 
to start a DMT represents, to some extent, a gamble. In addition, the clinical endpoints of trials 
measuring the efficacy of DMTs can be difficult to translate into meaningful terms for PwMS. 
The trade-offs PwMS have to consider when choosing between different treatments involve all 
aspects of their current and future lives. For example, they need to consider how much negative 
impact from side effects on quality of life and daily routine is acceptable in order to potentially 
slow down accrual of disability several years later. Moreover, many PwMS experience effects 
on cognition of their disease [12-16], which may impact on their ability to give considered 
responses in surveys. 
 
While general reviews of DCEs and BWS in health exist [17-20], none has specifically 
examined MS. Given the significant opportunities and challenges listed above, as well as a 
                                            
1
 Note that conjoint analysis is sometimes used as an umbrella term to refer to all studies which measure trade-
offs between attributes, and is also sometimes treated, including by papers in this review, as synonymous with 
DCE. Both these uses are incorrect [7]. DCEs (and in some interpretations, BWS [8]) are grounded in random 
utility theory and are choice based, making them conceptually different from conjoint analysis, which is grounded 
in mathematical psychology and is ranking/rating based. Therefore, in this paper we use the term attribute-based 
stated preference (AbSP). 
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recent rise in the number of relevant studies, a review focussing on this disease area is timely. 
This paper systematically reviews AbSP studies focusing on experiment design and conduct 
and suggests recommendations for improvement. 
 
2. Methods and materials 
 
2.1. Search strategy 
 
Comprehensive literature searches were developed by an information specialist using Medline, 
Embase, PsycINFO, CINAHL, Cochrane Libraries and the Web of Science Core Collections 
from database inception to 11 July 2017. Search concepts included multiple sclerosis and 
synonyms1 and AbSP related terms such as DCE, BWS, max diff and conjoint analysis. Subject 
headings and free text words were identified for use in the search concepts by the information 
specialist and project team members. Further terms were identified and tested from known 
relevant papers. Before running the searches, all search strategies were peer reviewed by a 
second information specialist using the Peer Review of Electronic Search Strategies (PRESS) 
checklist [21, 22].2 
 
The results of the database searches were stored and de-duplicated in an EndNote library. 
Further relevant studies were sought by citation searching (forwards and backwards) of the 
included studies. 
 
The searches identified 328 records.  Once duplicates were removed there were 214 records. 
Citation searches identified 0 records. Two authors (EW and DM) reviewed abstracts and 
selected 38 for fulltext review. The same two authors then selected for final inclusion articles 
which were (1) published in a peer-reviewed journal, (2) dealt exclusively or primarily with 
MS and (3) used an AbSP methodology in any part of the article. An AbSP methodology was 
defined as any method that uses quantitative data to examine preferences for attributes of a 
whole. Disagreements were resolved by consensus discussion between EW and DM. This 
resulted in 16 articles which reported 17 studies.  
 
                                            
1
 Specifically disseminated sclerosis and encephalomyelitis disseminata. 
2
 Please see Appendix A for full search strategies and date range. 
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2.2. Data extraction and analysis 
 
Table 1 lists the studies included for final analysis. Data was extracted using the form in 
appendix 0 by one author (EW). The data extraction form was developed by four authors (EW, 
DM, IE and AM) with the aim of focusing on study design features (study type, country of 
origin, participant inclusion criteria, sample size, attribute and levels identification and 
development) to assess whether studies had used best practice. Given the small numbers of 
studies it was not thought effective to pilot the form, however minor revisions were made 
during the process of data extraction. Analysis was performed using a narrative synthesis 
approach [23]. Detailed consideration was given to attribute development and presentation of 
information about probabilities, as these are often mentioned as key neglected areas in AbSP 
practice [24]. 
 
The quality of each study was scored by one author (EW) by using the International Society 
for Pharmacoeconomics and Outcomes Research (ISPOR) conjoint analysis checklist [25]. 
This contains 30 items which were given a count of 1 if a study reported considering at least 
some aspect of this item, and 0 if it did not. The final count for a study was then the sum of its 
counts for each item. A secondary aim of this study was to assess the suitability of using the 
checklist to assess the quality of AbSP studies for future reviews. This was done by considering 
whether it showed variation in overall counts and counts for individual items, as well as 
whether it revealed important issues previously unconsidered. 
 
Narrative synthesis of the identified studies was performed by several authors (EW, AM, IE, 
DM). Statistical analysis of numerical data was done by computing summary statistics using R 
version 3.3.1. 
 
3. Results 
 
All but one study examined patient preferences for DMTs, with the remaining study (Rosato, 
et al. [26]) looking at quality of life for PwMS. This focus is not surprising, as decisions about 
DMTs are of vital importance to PwMS and feature a mixture of benefits and risks, making 
AbSP an ideal quantitative tool with which to study the decision making of PwMS. 
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Fifteen studies (88.2%) were funded by pharmaceutical companies. One study, Rosato et al. 
[26] received funding from a public health authority and a charitable foundation, and one, 
Kremer et al. [27] states that the authors received no specific funding. 
 
Figure 2 shows the publication of MS AbSP studies over time. An upward time trend can 
clearly be seen, with the first appearing in 2009 and nine studies (52.9%) being published since 
2016. 
 
3.1. Study type 
 
Table 1 lists the AbSP method used by each study. The majority (nine, 52.9%) were DCEs. 
Two studies (11.8%) were BWS, of which one used case 1 (Kremer et al. [27]) and one used 
case 2 (Lynd et al. [28]). 
 
3.2. Survey population 
 
Table 1 lists in which country each study was carried out. The US was the most common 
country with seven (41.2%), with a further nine (52.9%) spread across Europe (Germany, Italy, 
the Netherlands, Spain, UK) and a single study in Canada. 
 
3.3. Diagnoses 
 
Seven studies (41.2%) included anyone with a diagnosis of MS, and seven (41.2%) included 
only patients with a diagnosis of RRMS. Of nine (52.9%) studies that clearly indicated 
diagnoses to exclude, all excluded PPMS. Seven studies (41.2%) required the diagnosis to be 
confirmed by a physician, seven (41.2%) relied on self-reported diagnoses, and in three studies 
(17.6%) it remained unclear how the diagnosis was established. 
 
3.4. Development of attributes and levels 
 
Most studies drew on existing literature in medicine and the social sciences (14, 82.4%) and/or 
healthcare professionals (12, 70.6%) to develop attributes and levels. Few used qualitative 
methods to elicit views of PwMS, with only two studies (11.8%) (Lynd, et al. [28], Kremer, et 
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al. [27]) employing focus groups. Seven studies (41.2%) used interviews at some point in the 
design stage, typically to refine an existing survey rather than as a basis for attribute 
development. Two out of these seven (28.6%) did not state how many interviews were carried 
out (Reed Johnson et al. [29], Poulos et al. [30]), and the average number for the remaining 
five is 10.3. Two studies (11.8%) (Wicks, et al. [31] studies 1 and 2) did not state how attributes 
and levels were developed. 
 
3.5. Survey design 
 
Figure 3a shows the number of attributes used by each study. The median number of attributes 
included in studies is six, in line with the typical number included in AbSP studies in health 
[18, 19, 32]. The minimum number of attributes was three, the maximum was 27. The median 
number of levels for each attribute is three, with a maximum of seven and a minimum of two. 
 
Fourteen studies (82.4%) used a fractional factorial design, and two studies (11.8%) (Wicks, 
et al. [31] studies 1 and 2) do not state the type of design used. Five studies (39.4%), all DCEs, 
selected their designs based on efficiency, and two (11.8%) explicitly reported using the 
criterion of D-efficiency.1 One study (Utz, et al. [34]) used a custom design with a contrast 
between DMT administration via pill or injection in every choice and all combinations of other 
attributes presented. Seven studies (41.2%) did not state which criteria were used to construct 
their design. The statistics program SAS (SAS Institute) was the most popular tool used to 
construct study designs with four studies (23.5%) and Sawtooth (Sawtooth Software) was the 
second most popular with three (17.6%). Five studies (29.4%) did not report how their designs 
were constructed. 
 
Only two out of 16 studies (12.5%) on DMT choice included an opt-out option (Carlin, et al. 
[26]) or justified why an opt-out was not included (Wilson, et al. [18]). 
 
A concern in designing AbSP surveys is how many choice tasks can be included without the 
survey becoming a burden to participants [25]. There was considerable variation in survey 
length, as can be seen in Figure 3b, which illustrates the number of choice tasks per subject in 
                                            
1
 A D-efficient design is one constructed using an algorithm to maximize the determinant of the information 
matrix and is commonly used in experimental design construction [33]. 
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each study. The median number was 12, with a standard deviation of 14.1, which is broadly in 
line with the wider AbSP health literature [18, 19, 32]. However, the number of choices is only 
one aspect of burden. Another aspect is the complexity of the task. For example, although Utz, 
et al. [34] presented 64 choice tasks, with only two options and three attributes each, the choices 
were relatively simple. Several studies increased the total number of choice tasks without 
increasing the burden on participants by using several different versions of the survey, with the 
median number being four. 
 
Two studies (11.8%) (Wicks, et al. [31] studies 1 and 2) did not report how many decisions 
participants made, making it difficult to assess whether the burden was appropriate or not, nor 
did they report how many survey versions were used. Nine (53.9%) assessed response quality 
and/or its impact on results (e.g. by presenting the same choice twice, giving a dominated 
option or eliciting if participants SLFNHG WKH VDPH DOWHUQDWLYH IRU HYHU\ TXHVWLRQ ³VWUDLJKW-
lininJ´ which can be used as an indication both of understanding and that burden was not 
excessive.  
 
Figure 3 illustrates the sample sizes obtained for final analysis and it can be seen that there is 
considerable variation. The median sample size was 189 (s.d. 162). Only a single study (Wicks, 
et al. [31] study 1) reported explicit power calculations and only six (35.3%) reported other 
sample size considerations such as ³rules of thumb´. 
 
Eleven studies (64.7%) were administered online and five (29.4%) were administered using 
pen and paper. Only two studies (Wilson, et al. [35] Bottomley, et al. [36]) reported, in line 
with item 7.2 of the ISPOR conjoint analysis checklist [25], a justification of the chosen mode 
of administration. 
 
3.6. Attributes 
 
The attributes used by each study were collated and placed in 13 categories by one author 
(EW). All attributes were assigned to at least one category and some were assigned to two 
categories (for example ³route and frequency of administration´ was classed both as route of 
administration and frequency of administration). 
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Among the most common attributes were effect on relapse (13, 76.5%), effect on progression 
(12, 70.6%), as well as severe side effects (12, 70.6%) and mild side effects (13, 76.5%). Also 
common were route (10, 58.8%) and frequency (13, 76.5%) of administration. Only four 
(23.5%) looked at monitoring of treatment, and another four (23.4%) included further 
miscellaneous aspects of administration. Six studies (35.3%) explored attributes related to the 
alleviation of MS symptoms. Three (17.6%) included attributes explicitly related to quality of 
life, one of which (Rosato et al [26]) ORRNHGVSHFLILFDOO\DW3Z06¶YDOXDWLRQof health-related 
quality of life. Four (23.5%) included attributes related to MRI scans. Two (11.8%) include an 
attribute relating to reproduction (male and female) and two (11.8%) had miscellaneous 
attributes that fitted into no other category. 
 
Eight studies (47.1%) looked at what mode of administration of DMTs PwMS prefer.1 All 
included the options of oral medication and injection, though only 3/8 (37.5%) distinguished 
between subcutaneous and intramuscular injection, and 5/8 (62.5%) included intravenous 
infusion.2 All but one of these studies (Utz, et al. [34]) combined mode and frequency of 
administration into a single attribute with the disadvantage of making it impossible to fully 
disentangle their effects. On the other hand, in practice there is a certain amount of correlation 
between mode and frequency, and combining them a priori rules out unrealistic combinations 
such as daily intravenous infusions or monthly pills. It also has the advantage of ³freeing up´ 
an attribute to describe some other aspect of treatment.  
 
3.7. Probability 
 
Both the benefits and risks  of DMTs are probabilistic in nature [10]. The majority of studies 
investigating preferences with DMTs (11 out of 17, 64.7%) did not explicitly quantify the 
probability of receiving a given benefit or experiencing a given adverse event. Only a single 
study (Reed Johnson, et al. [29]) clearly documented using visual means to convey probabilistic 
information3, using both a risk grid (a square grid with shaded squares indicating how many 
patients experience the relevant outcome, e.g. 5 shaded squares out of 1000 to indicate a 0.5% 
                                            
1
 Although 12 studies had mode of administration as an attribute as an attribute, two studies measured only how 
important it was in general to participants, without examining preferences between different modes. 
2
 Note that although infusion treatments are among the more modern treatments, it is not the case that the three 
studies that exclude them predate their introduction, coming from 2014, 2015 and 2016. 
3Wilson, et al. [35] VWDWHGWKDW³WKHYLVXDOULVNVFDOHZDVJLYHQIRUUHIHUHQFH´EXWGRHVQRWHODERUDWHIXUWKHU 
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risk) and a risk ladder (a scale giving the context of a given probability in terms of more familiar 
risks). No study examined how the presentation of probabilities influences preferences. 
 
3.8. Analysis methods 
 
Table 1 lists the main method of analysis for each study. The most popular method was mixed 
logit, with 10 out of 17 (58.8%) studies, far ahead of the next most popular method, latent class, 
with three out of 17 (17.6%). To analyse their data, four out of 17 (23.5%) studies used 
Sawtooth (Sawtooth Software). NLOGIT (Econometric Software) and SPSS (IBM) were each 
used by three studies (17.6%). Four studies (23.5%) did not report what software they used for 
analysis. 
 
3.9. Preference heterogeneity according to respondent characteristics 
 
Addressing the needs of individual patients is a crucial part of shared decision making [37], so 
it is important to go beyond mean preferences to examine how preferences vary according to 
the characteristics of PwMS. Only eight studies (47.1%) linked respondent heterogeneity to 
observed characteristics, for example by including them as covariates in a regression [34, 35] 
or using latent class analysis [26, 36]. However, some others accounted for heterogeneity by 
using models such as mixed logit without linking it to respondent characteristics. The aspects 
of heterogeneity considered by each study were categorised by one author (EW). Figure 3 
illustrates how many studies examined a given category. Seven out of eight studies (87.5%) 
tested for the influence of past or current treatment. Several studies explored heterogeneity 
according to demographic factors (age, gender, education), disease related factors (disease 
status/history, diagnosis) or quality of life related factors (for example the influence on lifestyle 
of pain and fatigue). 
 
3.10.  ISPOR conjoint analysis checklist quality assessment 
 
In general, all studies scored well against the ISPOR conjoint analysis checklist, with a median 
count of 23/30 (range 18 ± 27). Variation was low both in total counts as well as most counts 
for individual items. The checklist was not useful in highlighting otherwise unconsidered 
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issues. Due to this and its limited ability to discriminate between studies, we do not consider 
its use a success. 
 
4. Discussion 
 
We performed a systematic review of 17 AbSP studies in the field of MS. All but one study 
investigated the preferences of PwMS for aspects of DMTs, highlighting the importance of 
trade-offs when considering long term treatment of this chronic condition, which makes  DMTs 
an obvious topic for AbSP techniques.  
 
The most common survey method employed was DCE, which is consistent with a greater 
number of DCEs than other types of survey in healthcare in general. [20] found only 62 BWS 
studies in total published up until April 2016, whereas [19] found 179 DCEs between 2009 and 
2012 alone). It also reflects that the structure of DCEs, i.e. choosing between two or more 
alternatives, is closer to the target decision making situation of most studies, choosing between 
different DMTs, than other study types. 
 
A consequence of the focus on DMTs is the higher proportion of studies being directed only 
towards PwMS who have a diagnosis of RRMS (42.9%) where there are considerably more 
licensed DMTs available compared to progressive MS, for which so far only one drug, 
ocrelizumab (Ocrevus®) has been approved [38, 39]. However, this is still an improvement on 
the situation a few years ago. Patients with RRMS and PPMS are distinct groups, which differ 
in terms of past experience and projected disease course. This brings difficulties in capturing 
preference information from both groups using a single instrument. However, it also means 
that the preferences of people with different diagnoses may be very different from each other. 
Thus, ZKLOH WKH OLWHUDWXUH¶V IRFXVRQ3Z5506ZDV DSSURSULDWH LQ WKHSDVW WKHDQWLFLSDWHG
arrival of DMTs for progressive forms of MS means there is now also a need for research into 
the preferences of PwPPMS. 
 
The paucity of use of qualitative methods to develop attributes thus reflects an area for 
improvement, as well as better documentation of how attributes are developed and selected. It 
is not always appropriate to undertake extensive qualitative work in attribute development. (For 
example, [40] uses the well-known EQ-5D descriptions of health states as attributes, so 
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qualitative work developing attributes would be nonsensical.) However, PwMS are a 
heterogeneous population with a large variety of health-related experiences. To avoid omitting 
crucial aspects of decision making in AbSP studies, it is therefore vital to involve PwMS in 
attribute development. 
 
PwMS are in most cases non-medical professionals and as their disease progresses many suffer 
from cognitive impairment. Hence, even if attributes are largely dictated by the research 
question, qualitative interviews are useful in identifying the best way of meaningfully 
expressing attributes to participants. For example, a standard measure of the impact of a DMT 
RQ LQGLYLGXDOV¶ IXWXUHIXQFWLRQLQJ LQFOLQLFDO trials is the number of people experiencing an 
increase of 0.5-1 on the expanded disability status scale (EDSS) over a 3-6 month period [41]. 
Such a measure is difficult to translate into a concept meaningful to PwMS. Qualitative work 
is thus particularly needed when developing and selecting attributes for AbSP studies in MS. 
 
The majority of studies analysed their data using advanced modelling techniques such as mixed 
logit. However, several studies used a mixed logit model, but referred to it as a hierarchical 
Bayes model, or hierarchical Bayes analysis. This nomenclature is incorrect, as hierarchical 
Bayes is not a model itself, but rather an estimation method used to obtain the parameters of a 
model [42]. Many studies did not employ analytical techniques that examine response 
heterogeneity according to observed characteristics. 
 
Given the diverse manifestations and chronic deteriorating nature of MS, it is particularly 
important to consider response heterogeneity if studies are to accurately reflect the range of 
patient experiences and opinions. For example, it would be interesting to examine the influence 
on decision making of risk preference due to the risks associated with DMTs, or cognition, 
given the cognitive impairments many PwMS experience. Comparison of preferences and 
priorities of patients at different disease stages would also offer important insights into how 
experiences impact decisions. It should be noted, however, that including respondent 
characteristics when analysing AbSP data can be difficult due to the additional model 
parameters introduced. 
 
Only a single study offered and opt-out option. A significant number of PwMS choose not to 
take any DMT [43]. Hence, offering only a forced choice between DMTs means not capturing 
this aspect of their preferences. On the other hand, an opt-out also mean losing some 
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LQIRUPDWLRQDERXWUHVSRQGHQWV¶SUHIHUHQFHVEHWZHHQGLIIHUHQWRSWLRQVas well as risking that 
people choose the opt-out only to avoid making difficult choices [44]. Thus it is by no means 
appropriate for every study. However, studies which give only a forced choice should justify 
this decision and discuss its impact on their results. Future studies should also consider 
alternative to an opt-out such as a dual response design (respondents first make a forced-choice, 
then indicate if they would prefer to opt out). 
 
The design of a stated preference survey is crucial for the interpretation of its results [25, 45]. 
Many studies failed to report the criteria by which they constructed their design, making it 
impossible for the reader to judge whether it was done appropriately. In addition, different 
software packages, and different versions of software packages, each have their own algorithms 
for design construction. Thus, it is important for this to be reported for study reproducibility, 
which several studies did not. 
 
The studies reviewed employed a wide range of sample sizes, and it is often difficult to assess 
whether they have recruited appropriate numbers of participants. Several ³rules of thumb´ for 
AbSP sample size exist [46, 47] as well as guides for calculation [48]. Thus sample size 
considerations, whether explicitly calculated using priors or by less formal methods, are 
possible and usually necessary, and should be both undertaken and reported in future studies. 
If it is not known whether researchers have achieved an appropriate number of responses, it 
causes problems for assessing the quality and validity of its results. 
 
Only two studies ([35, 36]) justified the mode of survey administration used, although it should 
be noted that in many cases the authors may have felt the justification to be self-evident to the 
reader (e.g. a population drawn from an online community). Nevertheless, given the physical 
and cognitive impairments experienced by many PwMS which may impact the accessibility of 
surveys, it would be an improvement for future surveys to document that such factors have 
been considered. Studies using a convenience sample from a clinic should also show they have 
considered the impact of this choice on the representativeness of their responses. 
 
The most common attributes were related to prevention of relapses, progression, and side 
effects, which are probabilistic in nature. Yet the majority of studies presented the outcome of 
treatment decisions as certainties, e.g. respondents were certain to experience two relapses over 
the next four years. People¶s preferences for probabilistic outcomes are extremely 
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heterogeneous and can have a significant influence over their decision making. Thus, if 
SUHIHUHQFHVDUHHOLFLWHGRQO\IRUEHQHILWVFRVWVVWDWHVDVFHUWDLQWLHVHJ³UHODSVHVLQWKHQH[W
\HDUV´[49]) it calls into question the external validity of the results for preferences over real 
DMTs. It is difficult in general to appropriately communicate probabilities (see [50, 51] for 
overviews of current best practice). It can be even more difficult for participants to understand 
multiple probabilistic attributes. Thus for pragmatic reasons it is sometimes necessary to 
represent probabilistic aspects of treatments as certainties. However, given that a majority of 
studies have no probabilistic representation at all, the appropriate and regular inclusion of 
probabilistic aspects of DMTs is thus a feature of the literature in need of improvement. In 
addition, if probabilistic outcomes are represented as deterministic to aid respondent 
comprehension, the possible impact of this should be discussed. 
 
There is evidence that different ways of presenting probabilities influence individuals' 
understanding of them [51, 52], and also that understanding can be improved by using graphic 
presentation of probabilities [53, 54]. However, those studies that did use probabilistic 
attributes did not report whether they considered their mode of presentation appropriate. Only 
one study displayed probabilistic information visually using graphs or pictographs. None of 
the studies explored how choices are influenced by different modes of presentation. Likewise, 
no study examined the impact on PwMS' DMT preferences over Knightian uncertainty 
(outcomes whose probabilities of occurring are not explicitly quantified, or ³unknown 
unknowns´ [55]), although the long term effects of DMTs are in many cases unknown and 
even in the short term the risks of rare side effects may not be well quantified [56, 57]. 
 
Given so many aspects of MS and DMTs are characterised by poorly quantified risk and 
uncertainty, there is a need for better tools to communicate risk1, particularly against the 
backdrop of the cognitive impairment associated with MS. 
 
Only two studies included an attribute related to reproduction, and in neither of these two did 
it play a significant role in the analysis. We believe this to be an understudied area, due to 
previous research highlighting its importance [59, 60], the higher incidence of MS in women 
of child-bearing age [61], and the variation in advice regarding conception, pregnancy and 
                                            
1
 It should be noted that this recommendation could apply to AbSP studies in health in general, and not just 
limited to the field of MS [58]. 
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breastfeeding [62]. In addition, there is a lack of clinical research into the influence of DMTs 
on reproduction [63, 64] and some DMTs are contraindicated for men with MS trying to 
conceive [65]. 
 
The vast majority of studies (88.2%) were funded by pharmaceutical companies. These 
companies have many reasons to fund studies, for example information about patient 
preferences can be useful both in marketing existing drugs and informing future drug 
development. It can also be used to aid regulatory decisions, for example with the US Federal 
Drug Administration1. Pharmaceutical companies are the funders of nearly all the AbSp studies 
in MS. Thus nearly all of the literature addresses the aims of pharmaceutical companies. It 
would be welcome to have a broader range of funders, as this would bring a broader range of 
research objectives and greater diversity of studies. 
 
A strength of our work is its focus on the technical aspects of AbSP studies in MS. The number 
of such studies is increasing over time, and it can serve as a guide to the details of running 
them, and be a practical aid to future research. 
 
Another strength is that we have highlighted several areas of current practice which can be 
improved, particularly greater use of qualitative methods and better reporting of survey design 
choices. We have also highlighted gaps in the current literature. Future studies may wish to 
consider examining patient preferences surrounding DMTs and reproduction, how different 
methods of risk communication affect the decision making of PwMS, or the effect of Knightian 
uncertainty. 
 
Our study has several limitations. We have not quantitatively combined the results of studies. 
We took this decision partly because of our focus on study design, and also due to the 
difficulties of combining numerical results from studies using different methodologies and 
different ways of presenting results, as well as different attributes and level sets. Nevertheless, 
in the future, it would be informative to attempt a synthesis of results from AbSP studies in 
MS. 
 
                                            
1
 See e.g. 
https://www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm446680.
pdf.  
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Assessing study quality using the ISPOR conjoint analysis checklist is not recommended for 
future reviews of AbSP studies. It did not distinguish between minimum acceptable practice, 
for example basing attributes on a non-systematic review of clinical literature, and good 
practice, for example developing attributes through extensive qualitative research. That it was 
not a good measure of quality is perhaps unsurprising, as it was not created for that purpose, 
but rather as a rough guide to best practice when developing surveys [25]. 
 
Due to the focus on details of study design, unpublished studies such as conference proceedings 
were excluded, as we felt they included insufficient methodological information. 
 
5. Conclusion 
 
Shared decision making including patient preference views on treatment are increasingly used 
in medicine, particularly chronic conditions, such as MS, with a still evolving DMT landscape 
[66, 67]. Thus, it is important to investigate patient preferences, especially when the 
experiences of PwMS are very heterogeneous and there are many treatment options available. 
 
AbSP studies such as DCEs are increasingly used to measure PwMS¶SUHIHUHQFHV providing 
insights into this field. Several areas in need of improvement have been highlighted, 
particularly a greater use of qualitative methods in attribute and level development. Further 
work should be undertaken to better characterise the role of reproduction in decision making, 
and better communication of risk is warranted. 
 
Data availability statement: Data extracted from studies is included as supplementary 
material. 
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344, pp. 80-7, Sep 15 2014. 
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Figure 1: PRISMA flow diagram 
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Figure 2: Number of publications of attribute-based stated preference studies in multiple sclerosis per 
year 
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Figure 3: (a) Number of attributes included in each study; (b) number of questions answered per subject 
in each study; (c) sample sizes for final analysis for each study; (d) number of studies examining a given 
aspect of preference heterogeneity. 
(a) (b)
(c) (d)
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Table 1: Studies included for review. ES = Spain, NL = Netherlands, CA = Canada, DE = Germany, IT = 
Italy, DMT = disease modifying treatment, DCE = discrete choice experiment, BWS = best-worst scaling, 
MDU = multidimensional unfolding, LR = linear regression, LC = latent class, MNP = multinomial probit, 
MIX = mixed logit, SMR = stepwise multilinear regression, CL = conditional logit. 
Study Country Topic Type Analysis Sample Size 
No. of 
attributes 
Mean 
levels 
per 
attribute 
Questions 
per survey 
Arroyo et al. 
(2017) [68] ES DMTs Rating LR 221 5 2.6 10 
Bottomley et 
al. (2017) 
[36] 
UK DMTs DCE LC 350 7 3.29 12 
Carlin et al. 
(2017) [69] US DMTs DCE MNP 537 4 5 6 
Garcia-
Dominguez 
et al. (2016) 
[70] 
ES DMTs DCE MIX, SMR 125 6 2.67 12 
Kremer et al. 
(2016) [27] NL DMTs 
BWS 
(case 1) MIX 185 27 1 17 
Lynd et al. 
(2016) [28] 
CA DMTs 
BWS 
(case 2) 
CL, LC 189 6 3.17 18 
Poulos et al. 
(2016a) [30] DE DMTs DCE MIX 192 6 3.17 8 
Poulos et al. 
(2016b) [49] US DMTs DCE MIX 189 6 3.17 8 
Reed 
Johnson et 
al. (2009) 
[29] 
US DMTs DCE MIX 651 5 4 10 
Rosato et al. 
(2015) [26] IT 
Quality 
of life DCE LC 152 5 3 14 
Sempere et 
al. (2017) 
[71] 
ES DMTs MDU MDU 37 5 1 5 
Shingler et 
al. (2013) 
[72] 
UK DMTs DCE MIX 99 6 3 19 
Utz et al. 
(2014) [34] DE DMTs DCE MIX 156 3 2.67 64 
Wicks et al. 
(2015) [31] 
study 1 
US DMTs DCE MIX 319 10 2.9 Not stated 
Wicks et al. 
(2015) [31]  
study 2 
US DMTs Rating MIX 319 9 2.11 Not stated 
Wilson et al. 
(2014) [73] US DMTs DCE MIX 291 6 3.33 20 
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Wilson et al. 
(2015) [35] US DMTs Ranking MME 50 8 4 16 
  
A systematic review of DCEs and conjoint analysis studies in people with Multiple Sclerosis 
30 
 
Appendix A Search strategy 
 
CINAHL (EBSCO) 1981- present 
Print Search History  Monday, July 10, 2017 5:00:08 PM   
S15 (S6 AND S14)   17 
S14 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13   3,286 
S13 TI preference* based OR AB preference* based   1,027 
S12 TI ((choice N1 (based or model* or experiment* or behavio#r*))) OR AB ((choice N1 (based or 
model* or experiment* or behavio#r*)))   1,018 
S11 TI ((maximum difference or maxdiff or max-diff)) OR AB ((maximum difference or maxdiff or 
max-diff))   664 
S10 TI ((BWS or best-worst)) OR AB ((BWS or best-worst).)   178 
S9 TI conjoint OR AB conjoint   345 
S8 TI stated preference*. OR AB stated preference*.   161 
S7 TI discrete choice*. OR AB discrete choice*   313 
S6 S1 OR S2 OR S3 OR S4 OR S5   12,050 
S5 (MH "Myelitis, Transverse+")   138 
S4 TI transverse myelitis OR AB transverse myelitis   188 
S3 TI encephalomyelitis disseminata OR AB encephalomyelitis disseminata   1 
S2 TI (((multiple or disseminated) N2 scleros*)) OR AB (((multiple or disseminated) N2 scleros*))   
7,716 
S1 (MH "Multiple Sclerosis+")   10,585   
 
COCHRANE 
Date Run: 10/07/17 21:56:12.926 
Description: 08-02-17 
x Cochrane Database of Systematic Reviews (Wiley) : Issue 7 of 12, July 2017 (n = 2) 
x Cochrane Central Register of Controlled Trials (Wiley) : Issue 6 of 12, June 2017 (n = 47) 
x Cochrane Methodology Register (Wiley) : Issue 3 of 4, July 2012 (n = 1) 
 
ID Search Hits 
#1 MeSH descriptor: [Multiple Sclerosis] explode all trees 2344 
#2 (multiple scleros* or disseminat* scleros*):ti,ab  5931 
#3 encephalomyelitis disseminata:ti,ab  0 
#4 Transverse Myelitis:ti,ab  29 
#5 MeSH descriptor: [Myelitis, Transverse] explode all trees 15 
#6 #1 or #2 or #3 or #4 or #5  6141 
#7 (discrete choice):ti,ab  134 
#8 (stated preference*):ti,ab  206 
#9 MeSH descriptor: [Choice Behavior] explode all trees 1192 
#10 conjoint:ti,ab  168 
#11 (BWS or best-worst):ti,ab  63 
#12 (maximum difference or maxdiff or max-diff):ti,ab  6416 
#13 (choice near/1 (based or model* or experiment* or behavio?r*)):ti,ab  203 
#14 (preference* based):ti,ab  2171 
#15 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14  10203 
A systematic review of DCEs and conjoint analysis studies in people with Multiple Sclerosis 
31 
 
#16 #6 and #15  50 
 
Database: Embase Classic+Embase <1947 to 2017 July 07>  
-------------------------------------------------------------------------------- 
1     multiple sclerosis/ (109982) 
2     ((multiple or disseminated) adj2 scleros*).ti,ab. (96116) 
3     encephalomyelitis disseminata.ti,ab. (61) 
4     transverse myelitis.ti,ab. (3088) 
5     myelitis/ (8456) 
6     or/1-5 [MS] (125799) 
7     discrete choice*.tw. (1795) 
8     "discrete choice experiment"/ (152) 
9     stated preference*.tw. (598) 
10     (BWS or best-worst).tw. (1472) 
11     (maximum difference or maxdiff or max-diff).tw. (1514) 
12     conjoint.tw. (3003) 
13     *patient preference/ (3035) 
14     (choice adj (based or model* or experiment* or behavio?r*)).tw. (4926) 
15     preference* based.tw. (1598) 
16     or/7-15 [DCE terms] (15250) 
17     6 and 16 (100) 
 
Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-
Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R) <1946 to  
10 July 2017 22:32> 
Search Strategy: 
-------------------------------------------------------------------------------- 
1     exp Multiple Sclerosis/ (52589) 
2     ((multiple or disseminated) adj2 scleros*).ti,ab. (64733) 
3     encephalomyelitis disseminata.ti,ab. (45) 
4     Myelitis, Transverse/ (1278) 
5     transverse myelitis.ti,ab. (1784) 
6     or/1-5 [MS] (73795) 
7     discrete choice*.tw. (1331) 
8     stated preference*.tw. (474) 
9     Choice Behavior/ (28072) 
10     conjoint.tw. (2295) 
11     (BWS or best-worst).tw. (1118) 
12     (maximum difference or maxdiff or max-diff).tw. (1191) 
13     (choice adj (based or model* or experiment* or behavio?r*)).tw. (4310) 
14     preference* based.tw. (1217) 
15     or/7-14 [discrete choice terms] (36717) 
16     6 and 15 (74) 
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Database: PsycINFO <1806 to July Week 1 2017>  
-------------------------------------------------------------------------------- 
1     multiple sclerosis/ (11174) 
2     ((multiple or disseminated) adj2 scleros*).ti,ab. (13441) 
3     encephalomyelitis disseminata.ti,ab. (5) 
4     transverse myelitis.ti,ab. (268) 
5     myelitis/ (484) 
6     or/1-5 [MS] (14257) 
7     discrete choice*.tw. (758) 
8     stated preference*.tw. (440) 
9     choice behavior/ (16685) 
10     (BWS or best-worst).tw. (259) 
11     (maximum difference or maxdiff or max-diff).tw. (79) 
12     (choice adj (based or model* or experiment* or behavio?r*)).tw. (7104) 
13     preference* based.tw. (774) 
14     preferences/ (16011) 
15     conjoint.tw. (3024) 
16     or/7-15 [DCE] (38306) 
17     6 and 16 (19) 
 
Web of Science Core Content (Clarivate Analytics) [11 July 2017] 
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, ESCI Timespan=1900-2017 
   
# 14 68  #13 AND #5  
# 13 42,767  #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6  
# 12 2,672 TOPIC: ("preference* based")  
# 11 27,848 TOPIC: ((choice NEAR/1 (based or model* or experiment* or behavio$r*)).)  
# 10 2,388 TOPIC: (("maximum difference" or maxdiff or max-diff))  
# 9 2,582 TOPIC: ((BWS or best-worst))  
# 8 6,444 TOPIC: (conjoint)  
# 7 2,837 TOPIC: ("stated preference*")  
# 6 5,261 TOPIC: ("discrete choice")  
# 5 102,838 #4 OR #3 OR #2 OR #1  
# 4 2,012 TOPIC: ("transverse myelitis")  
# 3 46 TOPIC: ("encephalomyelitis disseminata")  
# 2 101,604 TOPIC: (((multiple or disseminated) NEAR/2 scleros*))  
# 1 100,909 TOPIC: ("multiple sclerosis")  
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Appendix B Data extraction form 
1. Study context 
i. What is the type of study? 
ii. What topic is the focus of the study? 
iii. In what country/countries is the target population? 
iv. What is the diagnosis of the target population? 
v. Source of funding 
vi. Date of publication 
 
2. Participants 
 
i. How were patients contacted? 
ii. Criteria for inclusion 
iii. Initial sample size after screening 
iv. Number of participants completing at least part of the survey 
v. Number of participants failing to complete survey 
vi. Number of participants excluded for data quality 
vii. Criteria for inclusion in final analysis 
viii. Number of participants included in final analysis 
 
3. Attribute development 
 
i. Drawn from literature review? 
ii. Consultation with medical professionals? 
iii. Focus group? 
iv. If yes, what was size of focus group? 
v. Interviews? 
vi. If yes, how many interviews? 
vii. Tested using a pilot study? 
viii. If yes, how many participated? 
ix. Any other notable characteristics of attribute development 
 
4. Attributes 
 
i. Number of attributes 
ii. Number of levels for each attribute 
iii. List of attributes 
iv. List of levels for each attribute 
v. Method of risk presentation 
 
5. Survey design 
 
i. Number of options presented per decision 
ii. Number attributes presented for each option 
iii. Was a no treatment option included? 
iv. Anything else asked? 
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v. If so, what? 
vi. Dominant choice question included? 
vii. Total number of questions (not including dominant choices) 
viii. Number of questions per survey 
ix. Number of different surveys 
x. Type of design (full factorial, partial factorial, etc.) 
xi. How was design constructed? (Sawtooth, SAS, etc.) 
xii. What criteria were used to judge the design? 
xiii. Were any power/sample size calculations carried out? 
xiv. If no, was there any non-quantitive consideration of power/sample size? 
xv. Administration method 
 
6. Additional data collected 
 
i. Demographic information collected? 
ii. Disease history collected? 
iii. Experience with DMTs collected? 
iv. Any other data collected? 
v. If so, what? 
 
7. Analysis 
 
i. What was the main method of analysis? 
ii. Any secondary method(s) of analysis? 
iii. Software used for analysis 
iv. Were results presented using importance scores? 
v. Were results presented using time til progression as numeraire? 
vi. Were results presented using money as numeraire (i.e. WTP)? 
vii. Were results presented using maximum acceptable risk? 
viii. Were results presented using utilities? 
ix. Was participant heterogeneity examined in any other way? 
x. If so, what was examined? 
 
8. Conclusions 
 
i. What was the most valued positive attribute? 
ii. What was the second most valued positive attribute? 
iii. What was the most valued negative attribute? 
iv. What was the second most valued negative attribute? 
v. If looking at mode of administration, what was the most preferred method? 
vi. If looking at mode of administration, what was the least preferred method? 
vii. Summary of other findings 
